When 22-year-old Cole Schmidtknecht walked up to the pharmacy counter, he learned his Advair Diskus inhaler had jumped from under $70 to over $500. He walked away without the medicine. Within a week, ...

The Federal Trade Commission has reached a landmark settlement with Express Scripts, addressing allegations that the pharmacy benefit manager inflated drug prices, including for insulin, to boost ...

If you've been relying on Express Scripts for your 90-day refills and home delivery, 2026 brings a critical shift: a new 'Copay Assurance' program that caps out-of-pocket costs, paired with stricter ...

DoD can't continue to ignore this conflict of interest that arises when a company owns both a PBM and a pharmacy. That has ...

While it’s true the 340B program provides valuable revenue for hospitals, it’s irresponsible for policymakers in St. Paul to ignore how for-profit players are pilfering the program or the negative ...

Hospitals affiliated with Mount Sinai, the University of Michigan and the University of Kansas allege that CVS artificially ...

Milestone Pharmaceuticals Inc (MIST) reports a successful product launch and strategic trials, despite facing early-stage revenue hurdles and increased expenses.

Future commercial investments will be ROI-driven, with potential sales force expansion and increased patient activation efforts evaluated in late 2026 or early 2027. Current cash reserves of ...

The company initiated its next development program for etripamil, starting a Phase III AFib-RVR trial. “We have initiated our Phase III trial for atrial fibrillation with rapid ventricular rate or ...

KBIA’s Rebecca Smith brings us the story of how some local, independent pharmacies are finding ways to diversify and expand ...

CARDAMYST™ (etripamil) nasal spray launch for PSVT is gaining traction; breadth of unique prescribers supports potential future adoptionExpress ...

Detailed price information for Milestone Pharmaceuticals Inc (MIST-Q) from The Globe and Mail including charting and trades.